GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » SQI Diagnostics Inc (FRA:XSQ) » Definitions » Buyback Yield %

SQI Diagnostics (FRA:XSQ) Buyback Yield % : -1.08 (As of May. 25, 2024)


View and export this data going back to 2010. Start your Free Trial

What is SQI Diagnostics Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

SQI Diagnostics's current buyback yield was -1.08%.


SQI Diagnostics Buyback Yield % Historical Data

The historical data trend for SQI Diagnostics's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SQI Diagnostics Buyback Yield % Chart

SQI Diagnostics Annual Data
Trend Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -47.35 -34.78 -27.66 - -

SQI Diagnostics Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of SQI Diagnostics's Buyback Yield %

For the Diagnostics & Research subindustry, SQI Diagnostics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SQI Diagnostics's Buyback Yield % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, SQI Diagnostics's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where SQI Diagnostics's Buyback Yield % falls into.



SQI Diagnostics Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

SQI Diagnostics's Buyback Yield for the fiscal year that ended in Sep. 2022 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 2.109) / 0
=N/A%

SQI Diagnostics's annualized Buyback Yield for the quarter that ended in Mar. 2023 is calculated as

Buyback Yield=Net Issuance of Stock(Annualized) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) * Annualized Factor / Market Cap
=- (0 + 0.02) * 4 / 0
=N/A%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the annualized quarterly data, the Repurchase of Stock and Issuance of Stock data used here is four times the quarterly (Mar. 2023) data.


SQI Diagnostics Buyback Yield % Related Terms

Thank you for viewing the detailed overview of SQI Diagnostics's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


SQI Diagnostics (FRA:XSQ) Business Description

Traded in Other Exchanges
N/A
Address
36 Meteor Drive, Toronto, ON, CAN, M9W 1A4
SQI Diagnostics Inc is the leader in the field of lung health. The company develops and manufactures respiratory health and precision medicine tests that run on SQI's automated systems. The company is developing tests to simplify and improve COVID-19 antibody monitoring, rapid acute lung injury testing, donor organ transplant informatics, and immunological protein and antibody testing. Its geographical segments are the United States, Canada, and Europe. Canada accounts for more than half of its revenues.

SQI Diagnostics (FRA:XSQ) Headlines

No Headlines